Form 4: Imunon CEO Stacy Lindborg Receives Stock Options
SEC Form 4 Filing
Imunon's CEO, Stacy Lindborg, was granted stock options to purchase 112,500 shares of common stock at an exercise price of $1.22 on June 12, 2024.
Summary
- On June 12, 2024, Stacy Lindborg, the President and CEO of Imunon, Inc., received stock options.
- These options allow her to purchase 112,500 shares of Imunon's common stock at an exercise price of $1.22 per share.
- The options vest in equal installments of 1/4 on the one, two, three, and four year anniversaries of the grant date.
- The options expire on June 12, 2034.
- Following this transaction, Ms. Lindborg directly owns 239,166 shares of Imunon common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders. However, it's not a major event that would drastically alter the company's outlook.
Positives
- The granting of stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent while aligning their interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The vesting schedule of 1/4 per year over four years is also a common practice to ensure long-term commitment.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with increasing shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of stock option grant and transaction. |
| 06/12/2025 | First vesting date for 1/4 of the stock options. |
| 06/12/2034 | Expiration date of the stock options. |
| 06/14/2024 | Date of signature on the Form 4 filing. |
Keywords
Imunon, Stock Options, Form 4, Beneficial Ownership, Stacy Lindborg, CEO, IMNN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.